<DOC>
	<DOCNO>NCT00769132</DOCNO>
	<brief_summary>The purpose study evaluate potential effect ER niacin/laropiprant , ER niacin , laropiprant , placebo course seven day urinary level metabolite thromboxane A2 ( TxA2 ) , marker vivo platelet reactivity .</brief_summary>
	<brief_title>A Study Evaluate Effects Extended Release ( ER ) Niacin/Laropiprant , Laropiprant , ER Niacin , Placebo Urinary Prostanoid Metabolites Subjects With High Cholesterol ( 0524A-075 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Female subject may pregnant and/or agree use appropriate method contraception begin least 2 week prior administration first dose study drug first treatment period , throughout study least 2 week administration last dose study drug last treatment period . Subject judge good health base medical history , physical examination , vital sign measurement , laboratory safety test perform prestudy ( screen ) visit and/or prior administration initial dose study drug . Subject clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug . Subject nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month ; subject discontinue smoke use nicotine/nicotine contain product least approximately 3 month may enrol study discretion investigator Subject mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 10 year . Subjects situational depression may enrol study discretion investigator . Subject history stroke , chronic seizure , major neurological disorder . Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease . Subject history neoplastic disease ( include leukemia , lymphoma , malignant melanoma ) , myeloproliferative disease , regardless time since treatment . Subject history thrombotic platelet relate disorder include prior deep venous thrombosis . Subject treat coumadin , heparin , clopidogrel use agent within 2 week screen . Subject treat aspirin use agent within 3 week prior administration screen . Subject unable refrain anticipates use medication , include prescription non prescription drug herbal remedy begin approximately 2 week prior administration initial dose study drug , throughout study poststudy visit . Subject consumes excessive amount alcohol , define great 3 glass , alcoholic beverage distil spirit per day . Subject consumes excessive amount , define great 6 serving , coffee , tea , cola , caffeinated beverage per day . Subject major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit . Subject history significant multiple and/or severe allergy , anaphylactic reaction significant intolerability prescription nonprescription drug food . Subject currently regular user illicit drug history drug ( include alcohol ) abuse within approximately 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>